The Liquid Biopsy and Tumor Progression in Breast Cancer
11 – 20 of 112
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Risk-adjusted benchmarking of long-term overall survival in patients with HER2-positive early-stage Breast cancer : A Swedish retrospective cohort study
(
- Contribution to journal › Article
-
Mark
Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI) : a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study
(
- Contribution to journal › Article
-
Mark
The role of primary care in the cancer care continuum : a qualitative study of cancer survivors’ experiences
(
- Contribution to journal › Article
-
Mark
Gene expression in metastatic breast cancer—patterns in primary tumors and metastatic tissue with prognostic potential
(
- Contribution to journal › Article
-
Mark
Noninvasive Staging of Lymph Node Status in Breast Cancer Using Machine Learning : External Validation and Further Model Development
(
- Contribution to journal › Article
-
Mark
Performance of standardized cancer patient pathways in Sweden visualized using observational data and a state-transition model
(
- Contribution to journal › Article
-
Mark
Breast Cancer Diagnosis Using Extended-Wavelength–Diffuse Reflectance Spectroscopy (EW-DRS) : Proof of Concept in Ex Vivo Breast Specimens Using Machine Learning
(
- Contribution to journal › Article
-
Mark
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer : data from the randomized SBII:2 trial
(
- Contribution to journal › Article
-
Mark
Mammographic density in relation to breast cancer recurrence and survival in women receiving neoadjuvant chemotherapy
(
- Contribution to journal › Article
-
Mark
Protocol for the T-REX-trial : Tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases - An open, multicentre, randomised non-inferiority phase 3 trial
(
- Contribution to journal › Article